Cetrelimab

Cetrelimab (JNJ 63723283; JNJ 3283) is a humanized IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo.
Read more
€0.00 (tax incl.)
Reference:
HY-P99499
Product Details
HY-P99499

Data sheet

Size
Multiple sizes
Reactivity
PD-1/PD-L1; Interleukin Related; TNF Receptor
Application
Cancer-programmed cell death
CAS
2050478-92-5

Menu

Settings